secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000059478-24-000185
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q2 revenue up 36% to $11.3B, raises FY revenue guidance by $3B
--------------------------------------------------------------------

- Q2 revenue $11.30B (+36% YoY); reported EPS $3.28 (+68%), non-GAAP EPS $3.92 (+86%).
- FY revenue guidance raised $3B; reported EPS raised $2.05 to $15.10-15.60; non-GAAP EPS raised $2.60 to $16.10-16.60.
- Growth driven by Mounjaro, Zepbound, and Verzenio; non-incretin revenue up 17% ex-Baqsimi rights sale.
- Pipeline: FDA approval of Kisunla for Alzheimer's; tirzepatide submissions for sleep apnea; positive SUMMIT and QWINT trials.
- Announced agreement to acquire Morphic Holding for oral integrin therapies; $5.3B manufacturing investment in Indiana.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947824000185/0000059478-24-000185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947824000185/lly-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000059478-24-000185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer